Factors influencing relapse in the long-term course of schizophrenia

Schizophrenia Research

Volumn 28, Issue 2-3, 1997, Pages 199-206

  Ayuso Gutiérrez, José L ^a   Del Río Vega, Julia Ma ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Depot neuroleptics; Family therapy; Psychosocial factors; Schizophrenia; Substance abuse

Indexed keywords

FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PLACEBO;

CONFERENCE PAPER; DISEASE COURSE; DRUG ABUSE; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; RELAPSE; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ANTIPSYCHOTIC AGENTS; FAMILY HEALTH; HUMANS; PATIENT COMPLIANCE; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 0344541102     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00131-X     Document Type: Conference Paper

References (53)

1. Appelbaum, P.S., Gutheil, T.G., 1980. Drug refusal: a study of psychiatric inpatients. Am. J. Psychiatry 33, 1443-1446.
2. Ayuso-Gutierrez, J.L., Paya, B., Saenz, M., del Rio, J.M., 1997. Schizophrenic relapse in medication-compliant and non-compliant patients. American Psychiatric Association Annual Meeting, San Diego, CA.
3. Brown, G.W., Birley, J.L.T., 1968. Crises and life changes and the onset of schizophrenia. J. Health Hum. Behav. 9, 203-214.
4. Carpenter Jr., W.T., Hanlon, T.E., Heinrichs, D.W., Summerfelt, B.S., Kirkpatrick, B., Levine, J., Buchanan, R.W., 1990. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Arch. Gen. Psychiatry 147, 1138-1148.
5. Cheung, H.K., 1981. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs? Br. J. Psychiatry 138, 490-494.
6. Chien, C.-P., 1975. Drugs and rehabilitation in schizophrenia. In: Greenblatt, M. (Ed.), Drugs in Combination With Other Therapies. Grune & Stratton, New York, pp. 13-34.
7. Crawford, R., Forrest, A., 1974. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br. J. Psychiatry 124, 385-391.
8. Crow, T., MacMillan, J.F., Johnson, A.L., Johnstone, E.C., 1986. The Northwick Park study of first episodes of schizophrenia. II: A randomised controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry 148, 120-127.
9. Curson, D.A., Barnes, T.R.E., Bamber, R.W., Platt, S.D., Hirsch, S.R., Duffy, J.C., 1985. Long-term depot maintenance of chronic schizophrenic outpatients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. Br. J. Psychiatry 146, 464-480.
10. Delva, N.L., Letemendia, F.J.J., 1982. Lithium treatment in schizophrenia and schizoaffective disorders. Br. J. Psychiatry 141, 387-400.
11. Dencker, S.J., Lepp, M., Malm, U., 1980. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatr. Scand. Suppl. 279, 64-77.
12. De Quardo, J.R., Carpenter, C.F., Tandon, R., 1994. Patterns of substance abuse in schizophrenia: nature and significance. J. Psychiatr. Res. 28, 267-275.
13. Drake, R.E., Wallace, M.A., 1988. Mental patients' attitudes toward hospitalization: a neglected aspect of hospital tenure. Am. J. Psychiatry 145, 29-34.
14. Falloon, I., Watt, D.C., Shepherd, M., 1978. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol. Med. 8, 59-70.
15. Gaebel, W., Pietzcker, A., 1985. One year outcome of schizophrenic patients: the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18, 235-239.
16. Haywood, T.W., Kravitz, H.M., Grossman, L.S., Cavanaugh Jr., J.L., Davis, J.M., Lewis, D.A., 1995. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry 152, 856-861.
17. Hirsch, S., Bowen, J.O., Emami, J., Cramer, P., Jolley, A., Haw, C., Dickinson, M., 1996. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Br. J. Psychiatry 168, 49-56.
18. Hogan, T.D., Awad, A.G., Eastwood, R., 1983. A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychol. Med. 13, 177-183.
19. Hogarty, G.E., Goldberg, S.C., Schooler, N.R., Ulrich, R.F.; the Collaborative Study Group, 1974. Drugs and sociotherapy in the aftercare of schizophrenic patients. II: Two-year relapse rate. Arch. Gen. Psychiatry 31, 603-608.
20. Hogarty, G.E., Ulrich, R.F., Mussare, F., Aristigueta, N., 1976. Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis. Nerv. Sys. 37, 494-500.
21. Hogarty, G.E., Andersen, CM., Reiss, D.J., Kornblith, S.J., Greenwald, D.P., Javna, C.D., Madonia, M.J.: Environmental/Personal Indicators in the Course of Schizophrenia Research Group, 1986. Family psychoeducation, social skills-training, and chemotherapy in the aftercare treatment of schizophrenia. Arch. Gen. Psychiatry 43, 633-642.
22. Johnson, D.A.W., 1979. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br. J. Psychiatry 135, 524-530.
23. Johnson, D.A.W., Pasterki, G., Ludlow, J.M., Street, K., Taylor, R.D.W., 1983. The discontinuation of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr. Scand. 67, 339-352.
24. Johnson, D.A.W., 1984. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J. Clin. Psychiatry 5, 13-21.
25. Johnson, D.A.W., Ludlow, J.M., Street, K., Taylor, R.D.W., 1987. Double-blind comparison of half-dose and standarddose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br. J. Psychiatry 151, 634-638.
26. Johnstone, E.C., 1992. Relapse in schizophrenia: what are the major issues. In: Hawton, K. (Ed.), Practical Problems in Clinical Psychiatry. Oxford University Press, Oxford.
27. Jolley, A.J., Hirsch, S.R., Morrison, E., McRink, A., Wilson, L., 1990. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. Br. Med. J. 301, 837-842.
28. Kane, J.M., Rifkin, A., Quitkin, F., Nayak, D., Ramos-Lorenzi, J., 1982. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch. Gen. Psychiatry 39, 70-73.
29. Kane, J.M., Rifkin, A., Woerner, M., Reardon, G., Sarantakos, S., Schiebel, D., Ramos-Lorenzi, J., 1983. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch. Gen. Psychiatry 40, 893-896.
30. Kane, J.M., 1987. Treatment of schizophrenia. Schizophr. Bull. 13, 133-156.
31. Kissling, W. (Ed.), 1994. Directrices para la prevencion de recidivas de la esquizofrenia con neurolepticos. Springer-Verlag Iberica, Barcelona.
32. Klimke, A., Klieser, E., 1995. Prevention of relapse in schizophrenia with clozapine: an open mirror-image study of 53 outpatients treated up to 8 years. Eur. Neuropsychopharmacol. 5, 343
33. Kraepelin, E., 1905. Introduction a la Clinica Psiquiátrica. Editorial Saturnino Calleja, Madrid.
34. Leff, J.P., Wing, J.K., 1971. Trial of maintenance therapy in schizophrenia. Br. Med. J. 3, 599-604.
35. Leff, J.P., Kuipers, L., Berkowitz, R., Eberlein-Vries, R., Sturgeon, D., 1982. A controlled trial of social intervention in families of schizophrenic patients. Br. J. Psychiatry 141, 121-134.
36. Lieberman, J.A. (1997) Evidence for sensitization in the early stage of schizophrenia. Biol. Psychiatry 42 (Suppl. 218), Abstract 79-4.
37. Malla, A.K., Cortese, L., Shaw, T.S., Ginsberg, G., 1990. Life events and relapse in schizophrenia. A one year prospective study. Soc. Psychiatry Psychiatr. Epidemiol. 25, 221-224.
38. Marder, S.R., Van Putten, T., Mintz, J., Lebell, M., McKenzie, J., May, P.R.A., 1987. Low-and conventional-dose maintenance therapy with fluphenazine decanoate. Arch. Gen. Psychiatry 44, 518-521.
39. Maurer. K., Biehl, H., 1988. Klinikanaufenthalte und produktive Ruckfalle bei ersterkrankten Schizophrenia. Nervenheilkunde 7, 279-290.
40. McCreadie, R.G., Dingwall, J.M., Wiles, D.H., Heykants, J.J.P., 1980. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br. J. Psychiatry 137, 510-517.
41. McCreadie, R.G., 1992. The Nithsdale schizophrenia surveys: an overview. Soc. Psychiatry Psychiatr. Epidemiol. 27, 40-45.
42. Moline, R.A., Singh, S., Morris, A., Meltzer, H.Y., 1985. Family expressed emotion and relapse in schizophrenia in 24 urban American patients. Am. J. Psychiatry 151, 314-320.
43. Müller, P. (Ed.), 1982. Zur Rezidivprophilaxe schizophrener Psychosen. Enke, Stuttgart.
44. Odejide, O.A., Aderounmu, A.F., 1982. Double-blind placebo subsitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J. Clin. Psychiatry 43, 195-196.
45. Pietzcker, A., Gaebel, W., Köpeke, W., Linden, M., Müller, P., Müller-Spahn, F., Tegeler. J., 1993. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia. J. Psychiatr. Res. 27, 321-339.
46. Regier, D.A., Boyd, J.H., Burke Jr., J.D., Rae, D.S., Myers, J.K., Kramer, M., Robins, L.N., George, L.K., Karno, M., Locke, B.Z., 1988. One-month prevalence of mental disorders in the United States. Arch. Gen. Psychiatry 45, 977-986.
47. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., Goodwin, F.K., 1990. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. J. Am. Med. Assoc. 264, 2511-2518.
48. Rifkin, A., Quitkin, F., Rabiner, C.J., Klein, D.F., 1977. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I: Relapse rates after one year. Arch. Gen. Psychiatry 34, 43-47.
49. Safer, D.J., 1987. Substance abuse by young adult chronic patients. Hosp. Community Psychiatry 38, 511-514.
50. Sartorius, N., Jablensky, A., Korten, A., Ernberg, G., Anker, M., Cooper, J.E., Day, R., 1986. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol. Med. 16, 909-928.
51. Tarrier, N., 1989. Community management of schizophrenia. A two year follow-up of a behavioral intervention with families. Br. J. Psychiatry 154, 625-628.
52. Weiden, P.J., Olfson, M., 1995. Cost of relapse in schizophrenia. Schizophr. Bull. 21, 4119-4129.
53. Wistedt, B., 1981. A depot neuroleptic withdrawal study. Acta Psychiatr. Scand. 64, 65-81.